Bridge Medicines

Bridge Medicines is a drug discovery company launched in collaboration with Memorial Sloan Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Limited, and healthcare investment firms Bay City Capital and Deerfield Management. Bridge Medicines is a groundbreaking initiative aimed at completing a seamless, well-funded, and professional path from concept to drug candidate, developing efficient and rapid innovative therapies for the treatment of human diseases.